Senores Pharmaceuticals Acquires USFDA-Approved ANDA for Tramadol Tablets

Senores Pharmaceuticals Limited, a world class research based pharmaceutical firm has made a disclosure that its 100% owned subsidiary (Senores Pharmaceuticals, Inc), USA has entered into an agreement to acquire the USFDA approved ANDA of Tramadol Tablets from APDM Pharmaceutical Private Limited. Tramadol is an opioid medication prescribed to relieve moderate to severe pains when other pain treatments fail to work.

This strategic purchase is in line with the overa ll growth and expansion of the product strategy of Senores and will be financed by the proceeds of Senores Initial Public Offering (IPO) as outlined in the firms red herring prospectus. IQVIA data shows that the value of the US market for Tramadol Tablets was approximately USD 61.95 million as of MAT December 2024 while Symphony data reports that they increased the value of that market to approximately USD 119.09 million in MAT March 2025.

Senores Pharmaceuticals Limited is involved in developing and producing a wide variety of pharmaceutical products that fall under numerous therapeutic categories and dosage forms for the US, Canada, and all other regulated and emerging markets. Senores Pharmaceuticals Limited has 61 ANDAs and 22 CMO/CDMO commercial products in the US in its portfolio.

Senores has a field in over 40 countries but has also obtained approval from over 10 international regulatory authorities for the Chhatral based facility that has over 260 product registrations and 530 applications. Senores also produces complex generics, critical care injectables and APIs. The firm has two formulation plants one at Atlanta, US and the other in Chhatral, India as well as two API plants in Gujarat, strengthening its global supply footprint for regulated and emerging markets.